Hematopoietic Cell Transplantation for Hodgkin Disease

Philip J. Bierman, Auayporn Nademanee

Research output: Chapter in Book/Report/Conference proceedingChapter


Patients infected with HIV are more likely to develop Hodgkin disease (HD), and HD has been described following solid organ transplantation. The poor results of conventional-dose salvage therapy for relapsed and refractory HD have led to the use of high-dose therapy (HDT) followed by autologous bone marrow transplantation (BMT) and peripheral blood hematopoietic cell transplantation (PBHCT) for these patients. Radiation is an essential tool in the treatment of HD. The prognosis for children and adolescents with HD is better than for adults and most are cured with primary therapy. Allogeneic HCT may result in a graft-versus-Hodgkin effect similar to the graft-versus-leukemia effect observed after allogeneic HCT for leukemia. Several groups of investigators have explored the use of reduced-intensity conditioning (RIC) allogeneic HCT for HD to exploit potential Graft-versus-Hodgkin disease (GVHL) effects and to reduce transplant-related mortality.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
Number of pages21
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
StatePublished - Jan 1 2016


  • Bone marrow transplantation
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • High-dose therapy
  • Hodgkin disease
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hematopoietic Cell Transplantation for Hodgkin Disease'. Together they form a unique fingerprint.

Cite this